Edison Pharmaceuticals

CompanyUnited StatesFounded 2005

RORWikidata

Edison Pharmaceuticals develops one asset, in phase 3, no development reported (Vatiquinone in Friedreich ataxia). Mostly small molecule acting on NQO1; based in the United States, founded in 2005.

1
Asset
Furthest stage
Phase 3, no development reported
Raised
$80.2M
4
Trials
0
Signals

Pipeline

1
  • Vatiquinone

    Inhibits 15-lipoxygenase to reduce lipid peroxidation and ferroptotic cell death.

    Phase 3, no development reported, Small molecule, NQO1, Friedreich ataxia, Alpers' disease (Phase 2)

Full company profiles: pipeline, trials, funding and people.

See Pro

In the full profile

  • Evidence behind the mechanisms1
  • Trials7
  • Funding rounds and grants6
  • Similar companies6

Intelligence